Skip Nav Destination
Issues
15 January 2013
-
Cover Image
Cover Image
Confocal immunofluorescent image showing the effects of the polycomb repressor complex 2 inhibitor 3-deazaneplanocin A on tumor cellularity and apoptosis in a xenotransplant model of human head and neck cancer. Immunodeficient mice were injected with a head and neck cancer cell line which was allowed to establish prior to daily treatment with 5 mg/kg DZNep. Tumor tissue has been stained with DAPI to highlight cell nuclei. Green immunofluorescence highlights the human epithelial tumor cells (AEI/III positive) and red fluorescence highlights caspase III positive dying cells. For details, see the article by Gannon and colleagues on page 428 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Statistics in Clinical Cancer Research
Molecular Pathways
Review
Human Cancer Biology
Cancer Therapy: Preclinical
Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies
Yicheng Mao; Georgia Triantafillou; Erin Hertlein; William Towns; Matthew Stefanovski; Xiaokui Mo; David Jarjoura; Mitch Phelps; Guido Marcucci; Ly James Lee; David M. Goldenberg; Robert J. Lee; John C. Byrd; Natarajan Muthusamy
BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies
Michelle R. Kuhne; Tanya Mulvey; Blake Belanger; Sharline Chen; Chin Pan; Colin Chong; Fei Cao; Wafa Niekro; Tom Kempe; Karla A. Henning; Lewis J. Cohen; Alan J. Korman; Pina M. Cardarelli
BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Chengwen Liu; Weiyi Peng; Chunyu Xu; Yanyan Lou; Minying Zhang; Jennifer A. Wargo; Jie Qing Chen; Haiyan S. Li; Stephanie S. Watowich; Yan Yang; Dennie Tompers Frederick; Zachary A. Cooper; Rina M. Mbofung; Mayra Whittington; Keith T. Flaherty; Scott E. Woodman; Michael A. Davies; Laszlo G. Radvanyi; Willem W. Overwijk; Gregory Lizée; Patrick Hwu
Imaging, Diagnosis, Prognosis
Variation in Precursor Lesions of Pancreatic Cancer among High-Risk Groups
Thomas P. Potjer; Ingrid Schot; Peter Langer; Johannes T. Heverhagen; Martin N.J.M. Wasser; Emily P. Slater; Günter Klöppel; Hans M. Morreau; Bert A. Bonsing; Wouter H. de Vos tot Nederveen Cappel; Mathias Bargello; Thomas M. Gress; Hans F.A. Vasen; Detlef K. Bartsch; on behalf of the Leiden Familial Pancreatic Cancer Group and the FaPaCa registry
Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors
Makoto Endo; Hidetaka Yamamoto; Nokitaka Setsu; Kenichi Kohashi; Yusuke Takahashi; Takeaki Ishii; Kei-ichiro Iida; Yoshihiro Matsumoto; Michiyuki Hakozaki; Mikiko Aoki; Hiroshi Iwasaki; Yoh Dobashi; Kenichi Nishiyama; Yukihide Iwamoto; Yoshinao Oda
Cancer Therapy: Clinical
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Evan J. Lipson; William H. Sharfman; Charles G. Drake; Ira Wollner; Janis M. Taube; Robert A. Anders; Haiying Xu; Sheng Yao; Alice Pons; Lieping Chen; Drew M. Pardoll; Julie R. Brahmer; Suzanne L. Topalian
Predictive Biomarkers and Personalized Medicine
Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment
Valentina Nardi; Peter M. Sadow; Dejan Juric; Dave Zhao; Arjola K. Cosper; Kristin Bergethon; Vanessa L. Scialabba; Julie M. Batten; Darrell R. Borger; Anthony John Iafrate; Rebecca S. Heist; Donald P. Lawrence; Keith T. Flaherty; Johanna C. Bendell; Daniel Deschler; Yi Li; Lori J. Wirth; Dora Dias-Santagata
Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
Heather E. Wheeler; Eric R. Gamazon; Claudia Wing; Uchenna O. Njiaju; Chidiamara Njoku; Robert Michael Baldwin; Kouros Owzar; Chen Jiang; Dorothy Watson; Ivo Shterev; Michiaki Kubo; Hitoshi Zembutsu; Eric P. Winer; Clifford A. Hudis; Lawrence N. Shulman; Yusuke Nakamura; Mark J. Ratain; Deanna L. Kroetz; for the Cancer and Leukemia Group B; Nancy J. Cox; Mary Eileen Dolan
CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
Matthew P. Goetz; Vera J. Suman; Tanya L. Hoskin; Michael Gnant; Martin Filipits; Stephanie L. Safgren; Mary Kuffel; Raimund Jakesz; Margaretha Rudas; Richard Greil; Otto Dietze; Alois Lang; Felix Offner; Carol A. Reynolds; Richard M. Weinshilboum; Matthew M. Ames; James N. Ingle
Retraction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.